Results for 'Global Field Medical Excellence'








Revamping the ever-changing landscape of drug development processes in the midst of COVID-19 pandemic
Apr 29th • 2 mins read

Biases in study design, implementation, and data analysis that distort the appraisal of clinical benefit and ESMO-Magnitude of Clinical Benefit Scale (ESMO-MCBS) scoring
Apr 20th • 8 mins read

Comparative study on anticancer drug access times between FDA, EMA and the French temporary authorisation for use program over 13 years
Apr 7th • 12 mins read

Are Quality of Randomized Clinical Trials and ESMO-Magnitude of Clinical Benefit Scale Two Sides of the Same Coin, to Grade Recommendations for Drug Approval?
Feb 11th • 3 mins read

Assessment of Coverage in England of Cancer Drugs Qualifying for US Food and Drug Administration Accelerated Approval
Feb 22nd • 10 mins read

Finding the Right Drug at the Right Dose the First Time: Has the Era of Personalized Formularies Finally Arrived?
Sep 27th • 1 min read

“Oncometabolism: The switchboard of cancer: An editorial”
Feb 1st • 1 min read

Loose Regulatory Standards Portend a New Era of Imprecision Oncology
Dec 1st • 4 mins read

A narrative review of biosimilars: a continued journey from the scientific evidence to practice implementation
Aug 3rd • 10 mins read


Safeguarding cancer research funding by European charities amidst the COVID-19 pandemic
Nov 22nd • 3 mins read

Seven decades of chemotherapy clinical trials: a pan-cancer social network analysis
Oct 16th • 12 mins read

Liquid biopsy in oncology: a consensus statement of the Spanish Society of Pathology and the Spanish Society of Medical Oncology
Sep 26th • 17 mins read